{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:53:54Z","timestamp":1753883634999,"version":"3.41.2"},"reference-count":21,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Insulinomas are rare neuroendocrine neoplasms and causes of hypoglycemia. They present with neuroglycopenic symptoms, including confusion and seizures. Suspected diagnosis must be confirmed through bloodwork and imaging. The majority of insulinomas are benign and cured surgically; less than 10% of insulinomas are malignant. Malignant insulinomas present a unique and rare challenge in managing persistent hypoglycemia and tumor burden. We present a case of a young woman who presented with Whipple triad and high-grade masses in her pancreas, liver, and distant lymph node metastases on imaging. Insulinoma was diagnosed. Hypoglycemia was managed with continuous dextrose infusion, diazoxide, and lanreotide. She was discharged on medical management and a continuous glucose monitor. Her metastatic disease is being treated with a capecitabine and temozolomide (CAPTEM) regimen showing 30% reduction in tumor burden. In conjunction with the National Institutes of Health, she is undergoing evaluation with numerous neuroendocrine tumor surgeons for cytoreductive surgery.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf005","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T10:39:31Z","timestamp":1737715171000},"source":"Crossref","is-referenced-by-count":0,"title":["Metastatic Insulinoma Managed With Continuous Glucose Monitoring in a Young Female Patient"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4748-1130","authenticated-orcid":false,"given":"Darya","family":"Bondarenko","sequence":"first","affiliation":[{"name":"Department of Medicine, Jefferson Abington Hospital , Abington, PA 19001 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-1589","authenticated-orcid":false,"given":"Franklin L","family":"Thelmo","sequence":"additional","affiliation":[{"name":"ChristianaCare Endocrinology Specialists, ChristianaCare Health System , Newark, DE 19713 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika K","family":"Shirodkar","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolic Diseases, Thomas Jefferson University Hospital , Philadelphia, PA 19107 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"volume-title":"Endotext","year":"2023","author":"de Herder","key":"2025020513064221100_luaf005-B1"},{"issue":"6","key":"2025020513064221100_luaf005-B2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","author":"Okabayashi","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2025020513064221100_luaf005-B3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1530\/ERC-20-0447","article-title":"CGM for insulinoma screening: a prospective and observational case-control study","volume":"28","author":"Ma","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025020513064221100_luaf005-B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPA.0000000000001735","article-title":"Continuous glucose monitoring in patients with insulinoma treated by endoscopic ultrasound-guided ethanol injection","volume":"50","author":"Yuan","year":"2021","journal-title":"Pancreas"},{"issue":"3","key":"2025020513064221100_luaf005-B5","first-page":"23-0056","article-title":"Continuous glucose monitoring in a patient with insulinoma presenting with unawareness of postprandial hypoglycemia","volume":"2023","author":"Nakajima","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"2025020513064221100_luaf005-B6","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.4158\/ACCR-2018-0590","article-title":"Use of a continuous glucose monitor for preoperative monitoring and treatment of hypoglycemia in a case of pancreatic neuroendocrine tumor","volume":"5","author":"Lyerla","year":"2019","journal-title":"AACE Clin Case Rep"},{"issue":"9","key":"2025020513064221100_luaf005-B7","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/curroncol31090403","article-title":"Insulinoma unmasked: a continuous glucose monitoring-fueled journey","volume":"31","author":"Koceva","year":"2024","journal-title":"Curr Oncol"},{"issue":"7","key":"2025020513064221100_luaf005-B8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4158\/EP.14.7.880","article-title":"Use of a continuous glucose monitor in the management of inoperable metastatic insulinoma: a case report","volume":"14","author":"Sawyer","year":"2008","journal-title":"Endocr Pract"},{"key":"2025020513064221100_luaf005-B9","first-page":"20-0132","article-title":"Successful medical management of insulinoma with diazoxide for 27 years","volume":"2020","author":"Warren","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"2025020513064221100_luaf005-B10","doi-asserted-by":"crossref","first-page":"e0246463","DOI":"10.1371\/journal.pone.0246463","article-title":"Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"2025020513064221100_luaf005-B11","first-page":"5","article-title":"Diazoxide for neonatal hyperinsulinemic hypoglycemia and pulmonary hypertension","volume":"10","author":"Newman-Lindsay","year":"2023","journal-title":"Children (Basel)"},{"issue":"9","key":"2025020513064221100_luaf005-B12","doi-asserted-by":"crossref","first-page":"e230020","DOI":"10.1530\/ERC-23-0020","article-title":"Emerging therapies for advanced insulinomas and glucagonomas","volume":"30","author":"Alexandraki","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025020513064221100_luaf005-B13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2337\/diacare.9.2.186","article-title":"Insulinoma in a 94-year-old woman: long-term therapy with verapamil","volume":"9","author":"Ulbrecht","year":"1986","journal-title":"Diabetes Care"},{"key":"2025020513064221100_luaf005-B14","doi-asserted-by":"crossref","first-page":"1322148","DOI":"10.3389\/fphar.2023.1322148","article-title":"Verapamil chronicles: advances from cardiovascular to pancreatic \u03b2-cell protection","volume":"14","author":"Arefanian","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"2025020513064221100_luaf005-B15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1159\/000508996","article-title":"Successful long-term medical management of unresectable insulinomas","volume":"13","author":"Spiro","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"4","key":"2025020513064221100_luaf005-B16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-19-0989","article-title":"Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study","volume":"182","author":"Veltroni","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2025020513064221100_luaf005-B17","doi-asserted-by":"crossref","first-page":"3519247","DOI":"10.1155\/2018\/3519247","article-title":"Capecitabine and temozolomide in neuroendocrine tumor of unknown primary","volume":"2018","author":"Chauhan","year":"2018","journal-title":"J Oncol"},{"issue":"3","key":"2025020513064221100_luaf005-B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/jco.2014.32.3_suppl.179","article-title":"Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors","volume":"32","author":"Fine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025020513064221100_luaf005-B19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000500135","article-title":"Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms","volume":"109","author":"Chatzellis","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2025020513064221100_luaf005-B20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1186\/s12885-022-10443-4","article-title":"A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera\u00ae in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)","volume":"22","author":"Deshayes","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"2025020513064221100_luaf005-B21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/2\/luaf005\/61617282\/luaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/2\/luaf005\/61617282\/luaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:09:10Z","timestamp":1738760950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf005\/7978312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,20]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf005","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,20]]},"article-number":"luaf005"}}